1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Affitech A/S - Product Pipeline Review - 2015

Affitech A/S - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 34 pages

Affitech A/S - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Affitech A/S - Product Pipeline Review - 2015’, provides an overview of the Affitech A/S’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Affitech A/S’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Affitech A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Affitech A/S’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Affitech A/S’s pipeline products

Reasons to buy

- Evaluate Affitech A/S’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Affitech A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Affitech A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Affitech A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Affitech A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Affitech A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Affitech A/S - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Affitech A/S Snapshot 5
Affitech A/S Overview 5
Key Information 5
Key Facts 5
Affitech A/S - Research and Development Overview 6
Key Therapeutic Areas 6
Affitech A/S - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Affitech A/S - Pipeline Products Glance 14
Affitech A/S - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Affitech A/S - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Affitech A/S - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
Affitech A/S - Drug Profiles 18
AT-001 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
AT-008 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
PGN-635 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
AT-009 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Monoclonal Antibodies to Antagonize GPCR for Inflammation and Oncology 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
AT-004 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
AT-005 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Affitech A/S - Pipeline Analysis 26
Affitech A/S - Pipeline Products by Target 26
Affitech A/S - Pipeline Products by Molecule Type 27
Affitech A/S - Pipeline Products by Mechanism of Action 28
Affitech A/S - Recent Pipeline Updates 29
Affitech A/S - Dormant Projects 31
Affitech A/S - Locations And Subsidiaries 32
Head Office 32
Other Locations and Subsidiaries 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
Affitech A/S, Key Information 5
Affitech A/S, Key Facts 5
Affitech A/S - Pipeline by Indication, 2015 7
Affitech A/S - Pipeline by Stage of Development, 2015 8
Affitech A/S - Monotherapy Products in Pipeline, 2015 9
Affitech A/S - Partnered Products in Pipeline, 2015 10
Affitech A/S - Partnered Products/ Combination Treatment Modalities, 2015 11
Affitech A/S - Out-Licensed Products in Pipeline, 2015 12
Affitech A/S - Out-Licensed Products/ Combination Treatment Modalities, 2015 13
Affitech A/S - Phase I, 2015 14
Affitech A/S - Preclinical, 2015 15
Affitech A/S - Discovery, 2015 16
Affitech A/S - Unknown, 2015 17
Affitech A/S - Pipeline by Target, 2015 26
Affitech A/S - Pipeline by Molecule Type, 2015 27
Affitech A/S - Pipeline Products by Mechanism of Action, 2015 28
Affitech A/S - Recent Pipeline Updates, 2015 29
Affitech A/S - Dormant Developmental Projects,2015 31
Affitech A/S, Subsidiaries 32

List of Figures
Affitech A/S - Pipeline by Top 10 Indication, 2015 7
Affitech A/S - Pipeline by Stage of Development, 2015 8
Affitech A/S - Monotherapy Products in Pipeline, 2015 9
Affitech A/S - Out-Licensed Products in Pipeline, 2015 12
Affitech A/S - Pipeline by Top 10 Target, 2015 26
Affitech A/S - Pipeline by Top 10 Molecule Type, 2015 27
Affitech A/S - Pipeline Products by Top 10 Mechanism of Action, 2015 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.